Pharmaceutical Executive Daily: Novo Nordisk Announces Price Reductions for GLP-1 Products
Feb 24, 2026
02:22
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
In today’s Pharmaceutical Executive Daily, AbbVie invests $380 million to expand API manufacturing capacity while Bora Pharmaceuticals and GSK enter a five-year manufacturing agreement, Novo Nordisk announces significant price reductions for its leading GLP-1 therapies, and Astellas enters a billion-dollar global collaboration with Vir Biotechnology to advance PSMA-targeting cancer treatments.
Pharmaceutical Executive